Marksans Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The promoters of Marksans Pharma Limited (Mark Saldanha and Sandra Saldanha) have submitted a declaration under SEBI Regulation 31(4) confirming that they have not created any encumbrance (pledge or charge) on their shareholding in the company. This is a regulatory filing submitted to both BSE and NSE on April 2, 2026. The disclosure serves as a periodic compliance requirement to inform exchanges about the status of promoter share pledges. A copy was also sent to the company's Audit Committee.
Positive signal for investors as it confirms promoters have not pledged their shares, reducing risk of potential share sales under margin calls. This filing is routine compliance and indicates no immediate dilution threat from encumbered promoter holdings.